ArticleFrontiers in immunology2026
Evaluation of cyclophosphamide for steroid-refractory hepatic acute graft-vs-host disease after allogeneic hematopoietic stem cell transplantation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Steroid-refractory (SR) hepatic acute graft-versus-host disease (aGVHD) remains a life-threatening complication following allogeneic hematopoietic stem cell transplantation, characterized by limited responsiveness to both first- and second-line therapies and an overall poor prognosis. This study aimed to evaluate the efficacy and safety of cyclophosphamide (CTX) as a salvage treatment for SR- hepatic aGVHD. Methods: A total of 50 patients with SR-hepatic aGVHD who underwent CTX treatment were retrospectively included in the analysis. Seventeen patients (34.0%) received CTX as second-line therapy, whereas the majority (n=33, 66.0%) were administered CTX as salvage therapy following failure of prior second-line interventions. Results: The overall response rate (ORR) at day 28 was 70.0%, with a durable ORR of 66.0% at day 56. Patients with the hepatitic variant of aGVHD showed a superior response compared to those with the classic variant (complete response: 6 of 8 [75.0%] vs. 14 of 42 [33.3%], P = 0.042). The probabilities of overall survival (OS) and nonrelapse mortality (NRM) at 3 years after CTX treatment were 36.9% (95% CI, 24.8%-54.9%) and 56.5% (95% CI, 41.4%-71.6%). Using propensity score matching (PSM), we compared 35 patients receiving CTX with 35 BAT (best available treatment) controls during the same study period. CTX initiation occurred later than BAT (median line: 3 vs 2, P < 0.001). Response rates and survival outcomes were comparable between two groups and CTX demonstrated consistent efficacy even when used as later-line therapy. Additionally, CTX did not significantly increase the risk of adverse events compared to the BAT group up to day 28. The most common adverse events in both groups were neutropenia (71.4% in the CTX group vs. 62.9% in the BAT group, P = 0.445), anemia (68.6% vs. 60.0%, P = 0.454), and cytomegalovirus infection (51.4% vs. 45.7%, P = 0.632). Discussion: These findings suggest that CTX is a promising and well-tolerated treatment option for patients with SR-hepatic aGVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.